Three months of rifapentine and isoniazid for latent tuberculosis infection
- PMID: 22150035
- DOI: 10.1056/NEJMoa1104875
Three months of rifapentine and isoniazid for latent tuberculosis infection
Abstract
Background: Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.
Methods: We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.
Results: In the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P=0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001).
Conclusions: The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.).
Comment in
-
Practical preventive therapy for tuberculosis?N Engl J Med. 2011 Dec 8;365(23):2230-1. doi: 10.1056/NEJMe1111859. N Engl J Med. 2011. PMID: 22150042 No abstract available.
-
Rifapentine and isoniazid for latent tuberculosis.N Engl J Med. 2012 Apr 12;366(15):1447. doi: 10.1056/NEJMc1200489. N Engl J Med. 2012. PMID: 22494127 No abstract available.
-
Rifapentine and isoniazid for latent tuberculosis.N Engl J Med. 2012 Apr 12;366(15):1447-8. doi: 10.1056/NEJMc1200489. N Engl J Med. 2012. PMID: 22494128 No abstract available.
Similar articles
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. N Engl J Med. 2019. PMID: 30865794 Free PMC article. Clinical Trial.
-
Updates in the Treatment of Active and Latent Tuberculosis.Semin Respir Crit Care Med. 2018 Jun;39(3):297-309. doi: 10.1055/s-0038-1660863. Epub 2018 Aug 2. Semin Respir Crit Care Med. 2018. PMID: 30071545 Review.
-
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. Ann Intern Med. 2017. PMID: 29114781 Free PMC article. Clinical Trial.
-
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.
-
Treatment of latent tuberculosis infection.Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Ther Adv Respir Dis. 2013. PMID: 24056289 Review.
Cited by
-
Asynchronous Video Directly Observed Therapy to Monitor Short-Course Latent Tuberculosis Infection Treatment: Results of a Randomized Controlled Trial.Open Forum Infect Dis. 2024 Mar 26;11(4):ofae180. doi: 10.1093/ofid/ofae180. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38665171 Free PMC article. Clinical Trial.
-
Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB.IJTLD Open. 2024 Feb;1(2):90-95. doi: 10.5588/ijtldopen.23.0361. IJTLD Open. 2024. PMID: 38655375 Free PMC article.
-
Interpreter usage and associations with latent tuberculosis infection treatment acceptance and completion in the USA among non-U.S.-born persons, 2012-2017.PLoS One. 2024 Apr 16;19(4):e0298628. doi: 10.1371/journal.pone.0298628. eCollection 2024. PLoS One. 2024. PMID: 38625902 Free PMC article.
-
Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.Am J Trop Med Hyg. 2024 Mar 26;110(5):999-1005. doi: 10.4269/ajtmh.23-0233. Print 2024 May 1. Am J Trop Med Hyg. 2024. PMID: 38531107 Free PMC article.
-
Extracellular vesicles as carriers of mRNA: Opportunities and challenges in diagnosis and treatment.Theranostics. 2024 Mar 11;14(5):2265-2289. doi: 10.7150/thno.93115. eCollection 2024. Theranostics. 2024. PMID: 38505610 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical